Meena Jain

Meena Jain serves as the Vice President of Clinical Development at Akero Therapeutics, focusing on late phase clinical development of Efruxifermin for treating MASH since May 2024. Previously, Meena held the position of Senior Director of Clinical Development at Spark Therapeutics, leading global systemic gene therapy clinical programs for lysosomal storage disorders from June 2022 to May 2024. Prior experience includes serving as Global Clinical Programme Director at CSL Behring, where Meena was responsible for clinical development in benign hematology from May 2019 to May 2022, and various roles at MedImmune, including Director of Clinical Development in Cardiovascular Renal and Metabolism and Associate Director for Respiratory. Meena's earlier career included leadership in Medical Affairs at Napp Pharmaceuticals and a clinical research position at Mundipharma Research Limited. Meena holds an MA MB BChir PhD in Medicine from the University of Cambridge and several qualifications in Pharmaceutical Medicine and Internal Medicine.